Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPSNASDAQ:CRDLNASDAQ:HUMANASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$4.80+6.0%$3.72$2.49▼$8.54$449.10M2.25861,804 shs1.21 million shsCRDLCardiol Therapeutics$1.41+2.2%$1.08$0.77▼$3.12$116.48M1.03354,973 shs173,836 shsHUMAHumacyte$2.59-1.1%$1.79$1.15▼$9.79$401.76M23.81 million shs6.63 million shsMREOMereo BioPharma Group$2.74+11.4%$2.29$1.58▼$5.02$435.66M0.531.13 million shs2.19 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways+5.96%+15.94%+29.14%+28.34%-35.74%CRDLCardiol Therapeutics+2.17%+13.25%+31.16%+21.03%-44.71%HUMAHumacyte-1.15%-3.36%+112.30%-16.18%-65.56%MREOMereo BioPharma Group+11.38%+28.04%+14.64%+10.04%-21.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPSCOMPASS Pathways2.1535 of 5 stars3.51.00.00.03.80.80.6CRDLCardiol Therapeutics2.6138 of 5 stars3.74.00.00.02.60.00.6HUMAHumacyte2.4825 of 5 stars3.51.00.00.03.22.50.6MREOMereo BioPharma Group2.0511 of 5 stars3.61.00.00.03.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 3.00Buy$18.83292.36% UpsideCRDLCardiol Therapeutics 3.40Buy$8.67514.66% UpsideHUMAHumacyte 3.00Buy$11.71352.29% UpsideMREOMereo BioPharma Group 3.25Buy$7.71181.54% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, CMPS, HUMA, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/27/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$12.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/12/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$3.65 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AHUMAHumacyte$517K777.10N/AN/A$0.13 per share19.92MREOMereo BioPharma Group$1M435.66N/AN/A$0.36 per share7.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$118.46M-$1.99N/AN/AN/AN/A-63.85%-51.97%7/30/2025 (Estimated)CRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)HUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)Latest CRDL, CMPS, HUMA, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.158.918.91CRDLCardiol Therapeutics0.012.492.49HUMAHumacyteN/A1.101.10MREOMereo BioPharma GroupN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%CRDLCardiol Therapeutics12.49%HUMAHumacyte44.71%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%CRDLCardiol Therapeutics5.25%HUMAHumacyte5.10%MREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12093.56 million65.51 millionOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableHUMAHumacyte150155.12 million111.76 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionableCRDL, CMPS, HUMA, and MREO HeadlinesRecent News About These CompaniesInvestors Buy Large Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO)June 7 at 1:23 AM | americanbankingnews.comInvestors Purchase Large Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO)June 6 at 11:34 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Mereo BioPharma Group plc (NASDAQ:MREO)June 5 at 4:05 AM | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Given Consensus Recommendation of "Buy" by AnalystsMay 31, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 618,784 Mereo BioPharma Group plc (NASDAQ:MREO)May 27, 2025 | marketbeat.comTema Etfs LLC Invests $3.12 Million in Mereo BioPharma Group plc (NASDAQ:MREO)May 20, 2025 | marketbeat.comJanus Henderson Group PLC Boosts Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)May 16, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comWhy Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%May 16, 2025 | aaii.comWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comMereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLCMay 15, 2025 | marketbeat.comMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | finanznachrichten.deMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Purchases Shares of 493,900 Mereo BioPharma Group plc (NASDAQ:MREO)May 8, 2025 | marketbeat.com225,000 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Purchased by Cantor Fitzgerald L. P.May 7, 2025 | marketbeat.comMereo acquires Dish FiberMay 2, 2025 | advanced-television.comMereo BioPharma Group plc (MREO): A Bull Case TheoryApril 18, 2025 | finance.yahoo.comIs Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA), Mereo Biopharma Group Plc (MREO) and Doximity (DOCS)April 9, 2025 | markets.businessinsider.comMereo BioPharma’s SWOT analysis: rare disease stock poised for breakthroughApril 2, 2025 | uk.investing.comMereo BioPharma initiated with an Overweight at JPMorganMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsCRDL, CMPS, HUMA, and MREO Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$4.80 +0.27 (+5.96%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$4.76 -0.04 (-0.92%) As of 06/6/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Cardiol Therapeutics NASDAQ:CRDL$1.41 +0.03 (+2.17%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.43 +0.02 (+1.42%) As of 06/6/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Humacyte NASDAQ:HUMA$2.59 -0.03 (-1.15%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.62 +0.03 (+1.16%) As of 06/6/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Mereo BioPharma Group NASDAQ:MREO$2.74 +0.28 (+11.38%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.78 +0.03 (+1.28%) As of 06/6/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
